Blood disorders
Lymphoma in Beijing
北京 淋巴瘤
22 hospitals in Beijing
Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Beijing may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 83 papers led
- 83 papers led
- 74 papers led
- 37 papers led
- 36 papers led
- 35 papers led
- 31 papers led
- 30 papers ledNo open trial led
- 25 papers ledNo open trial led
- 24 papers led
- 14 papers led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 4 papers ledNo open trial led
- 4 papers ledNo open trial led
- 2 papers ledNo open trial led
- 2 papers led
- 2 papers ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers led
Lymphoma in every city Beijing on the disease page, with the national map
open trials on lymphoma with a hospital in Beijing
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Beijing as lead sponsor or study site. 76 of them are led by a hospital in Beijing. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingThe Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy
- Phase
- Not given
- Started
- 2026-09
- Posted
- Registry
- NCT07039474
Age 18 years to 75 years (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Phase
- Phase 4
- Started
- 2026-03
- Posted
- Registry
- NCT07218341
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Lanzhou, Nanchang, Shanghai, Tianjin, Urumqi, Xuzhou, Zhengzhou
- RecruitingAn Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma
- Phase
- Early phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07344818
Age 18 years to Not stated (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Phase
- Phase 3
- Started
- 2026-02
- Posted
- Registry
- NCT07377578
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Nanning
- RecruitingA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07409428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou
- RecruitingExploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07441993
Age 18 years to Not stated (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Jinan, Nanchang, Nantong, Tianjin, Wuhan, Zhengzhou
- RecruitingA Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07519772
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Shanghai, Zhengzhou
- RecruitingPomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07523737
Age 18 years to 75 years (registered criteria)
Led by Beijing Tongren HospitalBeijing
- RecruitingCombination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07525466
Age 18 years to Not stated (registered criteria)
Led by Beijing Tongren HospitalBeijing
- RecruitingA Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07562022
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07570823
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingCD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07587840
Age 18 years to 85 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingJL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07603479
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
- Phase
- Early phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07606937
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin
- RecruitingSafety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA
- Phase
- Phase 1
- Started
- 2026-07
- Posted
- Registry
- NCT07620314
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Phase I Study of JLM019 Injection
- Phase
- Phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07623850
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Phase
- Phase 2/Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07634471
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai
- RecruitingA Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2026-07
- Posted
- Registry
- NCT07661537
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou
- RecruitingIn Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07775508
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingCD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07779018
Age 18 years to 85 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07808827
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingZanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07839247
Age 70 years to Not stated (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingRegistry of an Integrated Longitudinal Multimodal Biospecimen Biobank for Primary CNS Lymphoma in China
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07842835
Age 18 years to 100 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Jinan
- RecruitingRapid Diagnosis and Treatment Response Monitoring of Primary CNS Lymphoma Using CSF ctDNA Liquid Biopsy
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07851363
Age 18 years to 75 years (registered criteria)
Led by Beijing Tiantan HospitalBeijing
- RecruitingStudy of JMBI-001 in Patients With MYC-Positive Advanced Cancers
- Phase
- Phase 1/Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07864701
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingProspective ctDNA Testing in Large B-Cell Lymphoma
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07878351
Age 18 years to Not stated (registered criteria)
Led by Peking University People's Hospital; 1 listed hospital as study siteBeijing
- RecruitingBEX101 in B-cell Non-Hodgkin's Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07882641
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingMultimodal Ultrasound for Lymphoma Classification and Treatment Response Prediction
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07941063
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingOne Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT06618313
Age 18 years to Not stated (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingA Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06642792
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingA Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06697184
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Suzhou
- RecruitingA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06717347
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen
- RecruitingA Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06742996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Wenzhou, Wuhan, Xuzhou, Zhengzhou
- RecruitingSafety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06760039
Age 18 years to 80 years (registered criteria)
Led by Fifth Affiliated Hospital of Sun Yat-sen University; 5 listed hospitals as study sitesBeijing, Fuzhou, Lanzhou, Nanchang, Zhanjiang, Zhuhai
- RecruitingA Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06776952
Age 18 days to 70 days (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingStudy Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06792253
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingMZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06793189
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 2 listed hospitals as study sitesBeijing, Shanghai, Shenyang
- RecruitingA Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2025-01
- Posted
- Registry
- NCT06820268
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shijiazhuang, Wuhan
- RecruitingA Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2025-02
- Posted
- Registry
- NCT06822868
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad HospitalBeijing
- RecruitingClinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06829771
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Lanzhou, Luzhou, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Zhengzhou
- RecruitingCAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06834529
Age 14 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingNovel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT06838832
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingNanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06874946
Age 3 years to 70 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingComparison of ATLG and ATG for Immune Reconstitution After Allo-HSCT for Hematologic Malignancy
- Phase
- Phase 2/Phase 3
- Started
- 2025-05
- Posted
- Registry
- NCT06895538
Age 18 years to Not stated (registered criteria)
Led by Peking University First HospitalBeijing
- RecruitingA Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06911502
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Jinan, Wuhan
- RecruitingCD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06925464
Age 14 years to 70 years (registered criteria)
Led by Beijing GoBroad Hospital; 1 listed hospital as study siteBeijing, Shanghai
- RecruitingA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06943872
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuxi, Xiamen, Yangzhou
- RecruitingZanubrutinib Combined With G-CVP in Previously Untreated FL
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06959732
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- RecruitingA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT06973187
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Harbin, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xining, Xuzhou, Zhengzhou
- RecruitingA Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT07000617
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing
- RecruitingBCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07009002
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingCD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07022964
Age 14 years to 70 years (registered criteria)
Led by Beijing GoBroad Hospital; 1 listed hospital as study siteBeijing, Shanghai
- RecruitingDZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07059650
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07082686
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingTargeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Early phase 1
- Started
- 2025-08
- Posted
- Registry
- NCT07093411
Age 18 years to 75 years (registered criteria)
Led by Beijing GoBroad Hospital; 3 listed hospitals as study sitesBeijing, Hefei, Xi'an, Xuzhou
- RecruitingA Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07124936
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Kunming, Nanchang, Nanning, Shenyang, Suzhou, Taiyuan, Wuhan, Xi'an, Zhengzhou
- RecruitingGSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07138547
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07154264
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nantong, Shenyang, Wuhan, Yichang, Zhengzhou
- RecruitingOrelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
- Phase
- Phase 2/Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT07185373
Age 18 years to 75 years (registered criteria)
Led by Huashan Hospital; 11 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai, Xi'an, Zhengzhou
- RecruitingPA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07188610
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07189065
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingAn Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07200375
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingPomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
- Phase
- N/A
- Started
- 2025-08
- Posted
- Registry
- NCT07257510
Age 18 years to 80 years (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingPolymer-lipid Particle-delivered CAR1920 mRNA CAR-T Therapy for Relapsed/Refractory B-cell Lymphoma/Leukemia
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07321301
Age 14 years to 85 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingApplication of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma
- Phase
- Phase 4
- Started
- 2025-11
- Posted
- Registry
- NCT07355699
Age 18 years to Not stated (registered criteria)
Led by Beijing Tongren Hospital; 2 listed hospitals as study sitesBeijing, Shenyang
- RecruitingApplication of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07371923
Age 18 years to Not stated (registered criteria)
Led by Beijing Tongren HospitalBeijing
- RecruitingA Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Early phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07376642
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Hangzhou
- RecruitingEBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07450391
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingGlofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07460362
Age 18 years to 80 years (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingEnhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT07489989
Age 18 years to 85 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingGolidocitinib and Chidamide for Cutaneous T-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07754890
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingSHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-02
- Posted
- Registry
- NCT06122389
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingAzacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
- Phase
- Phase 1/Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06176027
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06219356
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Taiyuan, Wuhan, Xiamen, Zhengzhou
- RecruitingA Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2024-03
- Posted
- Registry
- NCT06313957
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer Hospital; 1 listed hospital as study siteBeijing, Zhengzhou
- RecruitingAllogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
- Phase
- Phase 1/Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06321289
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingTCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06323525
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06363994
Age 60 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingLinperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06376721
Age 18 years to 75 years (registered criteria)
Led by Beijing Tongren HospitalBeijing
- RecruitingICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06378138
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi
- RecruitingChidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06393361
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
- Phase
- Not given
- Started
- 2024-05
- Posted
- Registry
- NCT06436677
Age 18 years to 75 years (registered criteria)
Led by Peking University First Hospital; 2 listed hospitals as study sitesBeijing
- RecruitingStudy Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
- Phase
- Phase 1
- Started
- 2024-04
- Posted
- Registry
- NCT06445517
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Tianjin
- RecruitingOrelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06454968
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingCombination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06471738
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingGlofitamab in Chinese Patients With R/R DLBCL
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT06481826
Age 18 years to 80 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingStudy of AXT-1003 in Subjects With Advanced Malignant Tumors.
- Phase
- Phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06484985
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Shanghai
- RecruitingZanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06503263
Age 14 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingEvaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06521255
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou
- RecruitingPola-ZR2P in Previously Untreated DLBCL
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06664411
Age 14 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingPhase II Study of Golidocitinib and Benmelstobart in Patients with R/R ENKTL (JACKPOT50)
- Phase
- Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT06733051
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteBeijing, Guangzhou
- RecruitingGolidocitinib Plus CHOP in Newly Diagnosed PTCL
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06739265
Age 18 years to 70 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingSintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06824883
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingNanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
- Phase
- Phase 1/Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06880913
Age 12 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingA Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
- Phase
- Phase 1/Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06971523
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingZR-MTX for PIOL Phase II Trial
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06973811
Age 18 years to 75 years (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingValue of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph Nodes
- Phase
- Not given
- Started
- 2024-10
- Posted
- Registry
- NCT07155954
Age 18 years to Not stated (registered criteria)
Led by Peking University Third HospitalBeijing
- RecruitingA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT07234162
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingPredictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma
- Phase
- N/A
- Started
- 2024-07
- Posted
- Registry
- NCT07657494
Age 18 years to Not stated (registered criteria)
Led by Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing
- RecruitingCombination of CAR-DC Vaccine and ICIs in Malignant Tumors
- Phase
- Phase 1
- Started
- 2023-07
- Posted
- Registry
- NCT05631886
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingSelinexor in Combination With MTX+Ritu to Treat R/R CNSL
- Phase
- Phase 1/Phase 2
- Started
- 2023-08
- Posted
- Registry
- NCT05698147
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Hefei, Shanghai, Zhengzhou
- RecruitingA Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Posted
- Registry
- NCT05800977
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingA Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL
- Phase
- Phase 1/Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT05806099
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingFrontline of ASCT in High-risk DLBCL
- Phase
- Not given
- Started
- 2023-05
- Posted
- Registry
- NCT05831865
Age 18 years to 70 years (registered criteria)
Led by Peking University People's HospitalBeijing
- RecruitingClinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
- Phase
- Phase 2
- Started
- 2023-05
- Posted
- Registry
- NCT05833893
Age 14 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingCD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-07
- Posted
- Registry
- NCT05948033
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingTRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL
- Phase
- Phase 1/Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT06014073
Age 18 years to 70 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06066203
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingEfficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06082102
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Qingdao, Shanghai, Shenyang, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT06084936
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou
- RecruitingA Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
- Phase
- Phase 1/Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06090539
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Nanchang
- RecruitingA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06136559
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06170489
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingPola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
- Phase
- Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT06176729
Age 70 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingClinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
- Phase
- Phase 1
- Started
- 2023-12
- Posted
- Registry
- NCT06180174
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingAzacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
- Phase
- Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT06190067
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingRelma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06876688
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Phase
- Phase 1
- Started
- 2022-03
- Posted
- Registry
- NCT05091424
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Nanchang, Tianjin
- RecruitingA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Phase
- Phase 2/Phase 3
- Started
- 2022-01
- Posted
- Registry
- NCT05139017
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Luoyang, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingMecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
- Phase
- Phase 2
- Started
- 2022-04
- Posted
- Registry
- NCT05294055
Age 18 years to 65 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou
- RecruitingTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
- Phase
- Phase 1/Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05294731
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou
- RecruitingA Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
- Phase
- Phase 1/Phase 2
- Started
- 2022-07
- Posted
- Registry
- NCT05487170
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing
- RecruitingA Real World Study of Ensartinib in Advanced ALK-positive NSCLC
- Phase
- Not given
- Started
- 2022-05
- Posted
- Registry
- NCT05498064
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingA Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
- Phase
- N/A
- Started
- 2022-09
- Posted
- Registry
- NCT05514327
Age 18 years to Not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingTreAtments and outComes in paTients With prImary CutAneous Lymphoma
- Phase
- Not given
- Started
- 2022-08
- Posted
- Registry
- NCT05518851
Age not stated (registered criteria)
Led by Peking University First Hospital; 2 listed hospitals as study sitesBeijing, Jinan
- RecruitingAllogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05554939
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingA Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05623982
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Qingdao
- RecruitingCD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
- Phase
- Phase 2
- Started
- 2022-01
- Posted
- Registry
- NCT06081478
Age 14 years to 85 years (registered criteria)
Led by Beijing Tongren HospitalBeijing
- RecruitingEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Phase
- Phase 2
- Started
- 2021-04
- Posted
- Registry
- NCT04728893
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
- Phase
- Phase 1
- Started
- 2021-07
- Posted
- Registry
- NCT04993690
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou
- RecruitingFirst in Human, Dose Escalation Study of AN4005
- Phase
- Phase 1
- Started
- 2021-09
- Posted
- Registry
- NCT04999384
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Harbin, Wuhan
- RecruitingA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Posted
- Registry
- NCT05006716
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin, Wenzhou, Yichang, Zhengzhou
- RecruitingA Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
- Phase
- Phase 1
- Started
- 2021-03
- Posted
- Registry
- NCT06189391
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Jinan, Nanchang, Shanghai, Shijiazhuang, Tianjin, Xiamen, Zhengzhou
- RecruitingStudy to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Phase
- Phase 2
- Started
- 2020-01
- Posted
- Registry
- NCT03936153
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Lanzhou, Linyi, Shanghai, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou
- RecruitingEvaluate the Safety and Clinical Activity of HH2853
- Phase
- Phase 1/Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04390737
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
- RecruitingAssessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients
- Phase
- Phase 1/Phase 2
- Started
- 2020-06
- Posted
- Registry
- NCT04440436
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingStudy of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
- Phase
- Phase 1/Phase 2
- Started
- 2020-08
- Posted
- Registry
- NCT04494503
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan
- RecruitingPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
- Phase
- Phase 2
- Started
- 2020-10
- Posted
- Registry
- NCT04586478
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Wuhan, Zhengzhou
- RecruitingPhase Ib Clinical Study of Keynatinib
- Phase
- Phase 1
- Started
- 2020-09
- Posted
- Registry
- NCT04807881
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Chengdu, Shanghai
- RecruitingChina Lymphoma Patient Registry Study
- Phase
- Not given
- Started
- 2017-05
- Posted
- Registry
- NCT03313271
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- RecruitingID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
- Phase
- Not given
- Started
- 2016-10
- Posted
- Registry
- NCT02848274
Age not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- RecruitingCD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
- Phase
- Phase 1/Phase 2
- Started
- 2014-10
- Posted
- Registry
- NCT02259556
Age 16 years to 80 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingEstablishing Prospective Mediastinal Tumor Database of PUMCH
- Phase
- Not given
- Started
- 2012-01
- Posted
- Registry
- NCT06421805
Age not stated (registered criteria)
Led by Peking Union Medical College HospitalBeijing
- RecruitingTreatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy
- Phase
- Phase 2/Phase 3
- Started
- 2010-09
- Posted
- Registry
- NCT02657785
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- RecruitingTherapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
- Phase
- Phase 2/Phase 3
- Started
- 2010-09
- Posted
- Registry
- NCT02836158
Age 60 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingCAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation
- Phase
- Early phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT06986434
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingIMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
- Phase
- Phase 3
- Started
- 2026-02
- Posted
- Registry
- NCT07355283
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingSelinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07554482
Age 18 years to 75 years (registered criteria)
Led by Beijing Tongren HospitalBeijing
- Not yet recruitingTR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
- Phase
- Phase 3
- Started
- 2026-07
- Posted
- Registry
- NCT07639879
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingGoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma
- Phase
- Early phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07670260
Age 18 years to Not stated (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingEfficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07717580
Age 18 years to Not stated (registered criteria)
Led by Peking University First HospitalBeijing
- Not yet recruitingA Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07758491
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingA Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07784101
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingA Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07854639
Age 18 years to Not stated (registered criteria)
Led by Peking University First HospitalBeijing
- Not yet recruitingOrelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07896590
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingProphylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07917624
Age 18 years to 80 years (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMSBeijing
- Not yet recruitingA Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT06886139
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingJWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07024147
Age 18 years to Not stated (registered criteria)
Led by Peking University Cancer HospitalBeijing
- Not yet recruitingA Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone(T-CHP) in Previously Untreated Patients With CD20-positive DLBCL
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07035379
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingEvaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07187960
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chongqing, Guiyang, Haikou, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yantai, Zhengzhou
- Not yet recruitingA First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2024-04
- Posted
- Registry
- NCT06318884
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Zhengzhou
- Not yet recruitingA Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06368167
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
- Not yet recruitingChidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06563778
Age 18 years to 75 years (registered criteria)
Led by Chinese PLA General HospitalBeijing
- Not yet recruitingPralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma
- Phase
- N/A
- Started
- 2024-12
- Posted
- Registry
- NCT06671717
Age 18 years to 65 years (registered criteria)
Led by Peking University People's HospitalBeijing
- Not yet recruitingRelmacabtagene Autoleucel in Hematologic Malignancies
- Phase
- Not given
- Started
- 2023-12
- Posted
- Registry
- NCT06142188
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteBeijing
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Beijing
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Aerospace Center Hospital航天中心医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | 3 | 2 | none | 0 | none | none | none | none | none | none | 1 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Air Force General Hospital中国人民解放军空军特色医学中心 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing An Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Anding Hospital首都医科大学附属北京安定医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Anzhen Hospital首都医科大学附属北京安贞医院 | none | 6 | none | none | none | none | none | none | none | none | none | 1 | 0 | none | none | none | none | none | 2 | none | 0 | none | none | none | none | none | 0 | none | none | none | none | 19611 open | 805 open | none | none | 30 | none | 1 | none | none | none | 0 | none | none | 2 | 1 | 3 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | |
| Beijing Army General Hospital中国人民解放军总医院第七医学中心 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Boren Hospital北京高博博仁医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | 1 | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Chao-Yang Hospital首都医科大学附属北京朝阳医院 | none | 8 | 18 | 12 | 662 open | 18 | 21 | none | none | none | 2 | 6 | 0 | 1 | 2 | 52 | none | none | none | 2 | 0 | none | 0 | 0 | none | none | none | none | none | none | none | 342 open | 3 | 40 | none | 3 | none | 13 | none | 1 | none | none | none | none | 1 | none | 4 | none | none | none | 3 | 2 | 1 | none | none | none | 0 | none | none | none | none | |
| Beijing Chest Hospital首都医科大学附属北京胸科医院 | none | none | none | none | 802 open | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Children's Hospital首都医科大学附属北京儿童医院 | none | none | none | none | none | none | none | none | 4 | 6 | none | 5 | none | 331 open | 4 | none | 4 | 9 | 311 open | 25 | 1 | 33 | 2 | 0 | 1 | 2 | none | none | 2 | none | 15 | 6 | 24 | 17 | 4 | 3 | none | none | none | 1 | 0 | 0 | none | 1 | 1 | 1 | 7 | 0 | none | none | none | none | none | 13 | 1 | none | none | none | 0 | none | none | |
| Beijing Daxing District People's Hospital北京市大兴区人民医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Ditan Hospital, Capital Medical University首都医科大学附属北京地坛医院 | none | none | 72 | none | none | none | none | 5 | 0 | none | none | none | none | none | none | none | none | none | none | 7 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 11 | 0 | none | none | none | none | none | none | none | none | none | |
| Beijing Friendship Hospital首都医科大学附属北京友谊医院 | none | 12 | 511 open | 457 open | 38 | 10 | 401 open | none | 1 | 1 | none | 2 | 2 | 47 | 1 | 1 | none | none | 523 open | 30 | none | 0 | none | 0 | none | none | 12 | 1 | none | 41 open | 4 | 251 open | 0 | none | none | 2 | none | 1 | none | none | none | none | 1 | none | 1 | none | 0 | 2 | none | none | 121 open | 4 | none | 0 | none | none | none | none | none | none | none | |
| Beijing Fuwai Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing GoBroad Hospital北京高博医院 | none | 01 open | 01 open | none | none | none | 01 open | none | none | none | none | none | none | none | none | 02 open | 04 open | none | none | 25 open | none | none | none | none | none | none | 01 open | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Haidian Hospital北京市海淀医院 | none | none | none | none | 02 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Hospital北京医院 | none | none | 151 open | 4 | 74 | 10 | 25 | none | none | none | none | none | 0 | 1 | none | 2 | none | none | none | 6 | none | 2 | none | 0 | none | 0 | none | 11 | 41 open | none | none | 303 open | 3 | none | 0 | 1 | none | 8 | none | none | none | none | none | 0 | 2 | none | 1 | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | |
| Beijing Hospital, Capital Medical University北京市中西医结合医院 | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | 4 | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | |
| Beijing Huairou Hospital北京怀柔医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing HuiLongGuan Hospital北京回龙观医院 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Jishuitan Hospital北京积水潭医院 | none | none | none | none | none | none | none | none | none | none | 0 | 21 | none | none | 1 | 6 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Jishuitan Hospital Guizhou Hospital北京积水潭医院贵州医院 | none | none | none | none | none | none | none | none | none | none | 1 | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Jishuitan Hospital Liaocheng Hospital北京积水潭医院聊城医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Lu Daopei Hospital北京道培医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | 1 | none | 1 | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Luhe Hospital首都医科大学附属北京潞河医院 | none | none | none | none | none | 7 | none | none | none | 1 | none | 0 | 0 | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | |
| Beijing Rehabilitation Hospital首都医科大学附属北京康复医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Sanbo Brain Hospital北京三博脑科医院 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Shijitan Hospital北京世纪坛医院 | none | 1 | 9 | 14 | 47 | none | 28 | 13 | 0 | none | none | 1 | none | 0 | none | none | none | none | none | 4 | 0 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | 1 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Stomatological Hospital首都医科大学附属北京口腔医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 5 | none | none | none | none | none | none | none | none | none | none | none | |
| Beijing Tiantan Hospital首都医科大学附属北京天坛医院 | none | none | none | none | 18 | none | none | 30712 open | none | none | 14 | 0 | none | 0 | none | none | none | none | none | 242 open | none | 1 | none | none | none | 342 open | none | 1 | 609 open | none | none | 172 open | none | none | 6 | 1 | none | 2 | none | 4 | 0 | none | none | 1 | none | none | none | none | 0 | none | none | none | none | none | none | none | none | 1 | none | none | none | |
| Beijing Tongren Hospital首都医科大学附属北京同仁医院 | 6 | 1 | 30 | 15 | 34 | 8 | 14 | none | 8 | 21 | none | 7 | none | 9 | 1 | 6 | 01 open | none | 11 open | 357 open | none | 0 | none | none | none | 7 | 3 | 6 | none | 3 | none | 4 | 5 | 2 | 42 open | none | none | 1 | none | none | none | none | none | none | 1 | none | 2 | none | none | none | 2 | none | none | 1 | none | 0 | none | 4 | none | none | none | |
| Beijing Tsinghua Changgung Hospital北京清华长庚医院 | none | none | 29 | none | none | 4 | none | 12 | 1 | 0 | 0 | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 8 | none | none | 0 | 1 | 0 | none | 1 | none | 0 | none | none | none | 1 | 0 | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | |
| Beijing United Family Hospital北京和睦家医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | |
| Beijing Youan Hospital, Capital Medical University首都医科大学附属北京佑安医院 | none | none | 67 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | 2 | 6 | none | none | none | none | none | none | none | none | none | 5 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | 7 | 0 | none | none | none | none | none | none | none | none | none | |
| Beijng Anzhen Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College中国医学科学院肿瘤医院 | none | none | none | none | 9 | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Capital Medical University Electric Teaching Hospital北京电力医院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Capital Medical University Sanbo Brain Hospital北京三博脑科医院 | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Children's Hospital, Peking Union Medical College首都医科大学附属首都儿童医学中心 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | 2 | none | none | none | none | 2 | none | none | none | none | 0 | none | none | none | 1 | none | none | none | none | none | none | none | 2 | 3 | none | none | none | none | none | none | none | |
| China-Japan Friendship Hospital中日友好医院 | none | 5 | none | 13 | 563 open | 9 | none | none | none | none | none | 2 | none | none | none | 2 | none | none | 2 | 2 | none | none | none | none | none | 6 | 0 | none | none | none | none | 262 open | none | none | 0 | 01 open | none | 19 | 0 | none | 1 | 1 | 0 | 0 | none | none | 9 | none | none | none | 1 | 0 | none | none | none | none | 0 | none | none | none | none | |
| Chinese Medicine Affiliated Shenzhen Hospital北京中医药大学深圳医院(龙岗) | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chinese Medicine Third Affiliated Hospital北京中医药大学第三附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Chinese PLA General Hospital中国人民解放军总医院 | 8 | 27 | 1846 open | 1406 open | 176 | 712 open | 914 open | 561 open | 3 | 2 | none | 12 | 7 | 1 | 1 | 52 open | 06 open | 11 open | 21 open | 3730 open | 0 | 1 | 1 | none | none | 122 open | 52 open | 4 | 461 open | none | none | 765 open | 9 | 11 | 0 | 0 | 2 | 3 | 1 | 20 | 2 | 3 | 1 | 6 | 0 | 1 | 171 open | 1 | none | 0 | 2 | none | none | none | none | none | 0 | 1 | none | none | none | |
| Civil Aviation General Hospital民航总医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Dongfang Hospital北京中医药大学东方医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 5 | none | none | none | 1 | none | 5 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Dongzhimen Hospital北京中医药大学东直门医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 7 | none | none | none | none | none | 2 | none | 5 | none | none | none | none | none | 1 | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Dongzhimen Hospital北京中医药大学东直门医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fangshan Hospital, Beijing University of Chinese Medicine北京市房山区中医医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Jinzhou Medical University锦州医科大学附属第一医院 | none | 3 | none | 19 | 32 | none | 21 | 8 | none | none | none | 5 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Hospital of Tsinghua University北京华信医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 10 | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Integrative Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fu Wai Hospital中国医学科学院阜外心血管病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 34 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fu Wai Hospital中国医学科学院阜外心血管病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 21 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fu Wai Hospital, Peking Union Medical College中国医学科学院阜外心血管病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fuwai Hospital中国医学科学院阜外心血管病医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 1 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | 2432 open | 1503 open | none | none | 14 | none | none | none | none | none | 21 open | none | none | 5 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| FuWai Hospital, Peking Union Medical College | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fuxing Hospital首都医科大学附属复兴医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Guang Anmen Hospital中国中医科学院广安门医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guang'anmen Hospital中国中医科学院广安门医院 | none | none | none | 91 open | 321 open | 10 | 122 open | none | none | none | none | none | 1 | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | 3 | none | none | none | 20 | none | 2 | none | none | none | 1 | none | none | none | none | none | none | none | none | 5 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Medical Sciences Fuwai Hospital中国医学科学院阜外医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| National Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院 | 331 open | 18410 open | 1033 open | 1312 open | 58725 open | 452 open | 33335 open | 101 open | none | none | none | 8 | 1 | 2 | 1 | none | none | 3 | none | 832 open | 1 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Peking Union Medical College Fuwai Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Peking Union Medical College Hospital北京协和医院 | 3 | 41 open | 6510 open | 54 | 21313 open | 2279 open | 10610 open | 521 open | none | 0 | none | 4 | 6 | 71 open | 1 | 272 open | 1 | 161 open | 7 | 7410 open | 1 | 17 | 1 | 1 | none | 8 | 477 open | 6 | 9 | none | none | 294 open | 16 | 892 open | 3 | 27 | 0 | 18 | 14 | 44 | 31 open | 2 | 1 | 2 | 492 open | none | 5 | 1 | none | 14 | 221 open | 3 | 2 | 1 | 1 | 10 | none | none | 0 | none | none | |
| Peking University Aerospace Center Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Peking University Cancer Hospital北京大学肿瘤医院 | 2 | 826 open | 425 open | 2239 open | 16122 open | 342 open | 11614 open | none | none | none | none | 4 | 121 open | 1 | 2 | 3 | none | none | none | 834 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Peking University First Hospital北京大学第一医院 | none | none | 202 open | 271 open | 535 open | 283 open | 444 open | none | 0 | none | none | 41 open | 2 | 6 | 1 | 175 open | none | none | 1 | 366 open | none | 1 | 2 | none | none | 1 | 5 | 3 | none | none | none | 232 open | 5 | 71 open | 1 | 1 | 1 | 4 | none | 2 | 1 | 8 | 1 | 11 | 2 | 8 | 651 open | none | 0 | none | 0 | 1 | none | 1 | 5 | none | 1 | none | none | none | none | |
| Peking University International Hospital北大国际医院 | none | none | none | none | none | none | none | none | 1 | none | none | 0 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 6 | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Peking University People's Hospital北京大学人民医院 | none | 2 | 241 open | 213 open | 10214 open | 31 open | 4422 open | none | none | 0 | 6 | 442 open | 102 open | none | 82 open | 195 open | 194 open | 293 open | 71 open | 146 open | none | 01 open | none | 42 open | 2 | 01 open | 121 open | 3 | none | none | none | 13 | 5 | 7 | none | 1 | none | 3 | none | none | none | none | none | none | 51 open | none | 0 | 0 | none | 2 | 7 | 0 | 0 | none | none | none | 0 | none | none | none | none | |
| Peking University Shougang Hospital北京大学首钢医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | 1 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | 0 | none | none | none | none | none | none | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Peking University Third Hospital北京大学第三医院 | none | none | 121 open | 262 open | 514 open | 162 open | 282 open | 232 open | none | none | 6 | 7 | 2 | 0 | 0 | 7 | 0 | none | none | 313 open | 0 | 1 | none | 0 | none | 2 | 2 | none | 2 | none | none | 172 open | 5 | 41 | none | 1 | 0 | 2 | none | 522 open | 01 open | 1 | none | 1 | 0 | none | 1 | none | none | none | 0 | none | none | none | none | none | 0 | none | none | none | none | |
| Plastic Surgery Hospital中国医学科学院整形外科医院 | none | none | none | none | none | none | 20 | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Plastic Surgery Hospital, Peking Union Medical College | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| PUMC Hospital中国医学科学院北京协和医院 | none | none | none | none | none | 0 | none | none | none | none | none | 0 | 0 | none | 0 | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | |
| Sanbo Brain Hospital首都医科大学三博脑科医院 | none | none | none | none | none | none | none | 301 open | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Sanbo Brain Hospital, Capital Medical University | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Artillery General Hospital中国人民解放军火箭军特色医学中心 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shijitan Hospital, Captial Medical University首都医科大学附属北京世纪坛医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Wangjing Hospital中国中医科学院望京医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Xiyuan Hospital中国中医科学院西苑医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | 25 | none | none | none | none | none | 0 | none | 1 | none | none | none | none | none | none | 9 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Xuanwu Hospital首都医科大学宣武医院 | 2 | none | 15 | 5 | 262 open | 6 | 12 | 25 | none | 0 | 7 | 1 | none | 3 | none | none | 0 | none | none | 7 | 1 | none | none | 1 | none | 52 open | 2 | 161 open | 7 | none | none | 151 open | 5 | 122 open | 9 | 6 | none | none | none | 7 | none | none | none | 1 | 0 | none | 2 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | |
| Yuquan Hospital清华大学玉泉医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Beijing.
- Oesophageal squamous cell carcinoma 6
- Osteosarcoma 1
- Gastrointestinal stromal tumour 0
- Haemophagocytic lymphohistiocytosis 2
- Beta thalassaemia 0
- IgG4-related disease 0
- Coronary heart disease 19611 open
- Congenital heart disease 805 open
- Takayasu arteritis 30
- Idiopathic pulmonary fibrosis 1
- Fabry disease 0
- Behçet disease 2
- Alport syndrome 1
- IgA nephropathy 3
- Primary biliary cholangitis 1
- Oesophageal squamous cell carcinoma 8
- Hepatocellular carcinoma 18
- Stomach cancer 12
- Lung cancer 662 open
- Pancreatic cancer 18
- Breast cancer 21
- Chordoma 2
- Osteosarcoma 6
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Ewing sarcoma 2
- Multiple myeloma 52
- Lymphoma 2
- Beta thalassaemia 0
- Atypical haemolytic uraemic syndrome 0
- Thrombotic thrombocytopenic purpura 0
- Coronary heart disease 342 open
- Congenital heart disease 3
- Scoliosis 40
- Takayasu arteritis 3
- Idiopathic pulmonary fibrosis 13
- Amyotrophic lateral sclerosis 1
- Behçet disease 1
- IgA nephropathy 4
- Primary biliary cholangitis 3
- Primary sclerosing cholangitis 2
- Congenital diaphragmatic hernia 1
- Familial adenomatous polyposis 0
- Hepatoblastoma 4
- Retinoblastoma 6
- Osteosarcoma 5
- Neuroblastoma 331 open
- Ewing sarcoma 4
- B-cell acute lymphoblastic leukaemia 4
- Aplastic anaemia 9
- Haemophagocytic lymphohistiocytosis 311 open
- Lymphoma 25
- Beta thalassaemia 1
- Haemophilia A 33
- Atypical haemolytic uraemic syndrome 2
- Thrombotic thrombocytopenic purpura 0
- Fanconi anaemia 1
- Neuromyelitis optica spectrum disorder 2
- Moyamoya disease 2
- Biliary atresia 15
- Coronary heart disease 6
- Congenital heart disease 24
- Scoliosis 17
- Anti-NMDA receptor encephalitis 4
- Takayasu arteritis 3
- Amyotrophic lateral sclerosis 1
- Spinal muscular atrophy 0
- Fabry disease 0
- Duchenne muscular dystrophy 1
- Behçet disease 1
- Alport syndrome 1
- IgA nephropathy 7
- Gaucher disease 0
- Hirschsprung disease 13
- Inherited epidermolysis bullosa 1
- Majeed syndrome 0
- Oesophageal squamous cell carcinoma 12
- Hepatocellular carcinoma 511 open
- Stomach cancer 457 open
- Lung cancer 38
- Pancreatic cancer 10
- Breast cancer 401 open
- Hepatoblastoma 1
- Retinoblastoma 1
- Osteosarcoma 2
- Gastrointestinal stromal tumour 2
- Neuroblastoma 47
- Ewing sarcoma 1
- Multiple myeloma 1
- Haemophagocytic lymphohistiocytosis 523 open
- Lymphoma 30
- Haemophilia A 0
- Thrombotic thrombocytopenic purpura 0
- IgG4-related disease 12
- Myasthenia gravis 1
- Wilson disease 41 open
- Biliary atresia 4
- Coronary heart disease 251 open
- Congenital heart disease 0
- Takayasu arteritis 2
- Idiopathic pulmonary fibrosis 1
- Pompe disease 1
- Behçet disease 1
- IgA nephropathy 0
- Gaucher disease 2
- Primary biliary cholangitis 121 open
- Primary sclerosing cholangitis 4
- Hirschsprung disease 0
- Hepatocellular carcinoma 151 open
- Stomach cancer 4
- Lung cancer 74
- Pancreatic cancer 10
- Breast cancer 25
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Multiple myeloma 2
- Lymphoma 6
- Haemophilia A 2
- Thrombotic thrombocytopenic purpura 0
- Neuromyelitis optica spectrum disorder 0
- Myasthenia gravis 11
- Moyamoya disease 41 open
- Coronary heart disease 303 open
- Congenital heart disease 3
- Anti-NMDA receptor encephalitis 0
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 8
- Duchenne muscular dystrophy 0
- Behçet disease 2
- IgA nephropathy 1
- Inherited epidermolysis bullosa 0
- Lung cancer 18
- Glioma 30712 open
- Chordoma 14
- Osteosarcoma 0
- Neuroblastoma 0
- Lymphoma 242 open
- Haemophilia A 1
- Neuromyelitis optica spectrum disorder 342 open
- Myasthenia gravis 1
- Moyamoya disease 609 open
- Coronary heart disease 172 open
- Anti-NMDA receptor encephalitis 6
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 4
- Spinal muscular atrophy 0
- Duchenne muscular dystrophy 1
- Niemann–Pick disease type C 0
- Leber hereditary optic neuropathy 1
- Nasopharyngeal carcinoma 6
- Oesophageal squamous cell carcinoma 1
- Hepatocellular carcinoma 30
- Stomach cancer 15
- Lung cancer 34
- Pancreatic cancer 8
- Breast cancer 14
- Hepatoblastoma 8
- Retinoblastoma 21
- Osteosarcoma 7
- Neuroblastoma 9
- Ewing sarcoma 1
- Multiple myeloma 6
- B-cell acute lymphoblastic leukaemia 01 open
- Haemophagocytic lymphohistiocytosis 11 open
- Lymphoma 357 open
- Haemophilia A 0
- Neuromyelitis optica spectrum disorder 7
- IgG4-related disease 3
- Myasthenia gravis 6
- Wilson disease 3
- Coronary heart disease 4
- Congenital heart disease 5
- Scoliosis 2
- Anti-NMDA receptor encephalitis 42 open
- Idiopathic pulmonary fibrosis 1
- Behçet disease 1
- IgA nephropathy 2
- Primary biliary cholangitis 2
- Hirschsprung disease 1
- Hereditary angioedema 0
- Leber hereditary optic neuropathy 4
- Hepatocellular carcinoma 29
- Pancreatic cancer 4
- Glioma 12
- Hepatoblastoma 1
- Retinoblastoma 0
- Chordoma 0
- Osteosarcoma 2
- Congenital heart disease 8
- Takayasu arteritis 0
- Hepatic echinococcosis 1
- Idiopathic pulmonary fibrosis 0
- Amyotrophic lateral sclerosis 1
- Fabry disease 0
- Alport syndrome 1
- IgA nephropathy 0
- Primary sclerosing cholangitis 1
- Oesophageal squamous cell carcinoma 5
- Stomach cancer 13
- Lung cancer 563 open
- Pancreatic cancer 9
- Osteosarcoma 2
- Multiple myeloma 2
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 2
- Neuromyelitis optica spectrum disorder 6
- IgG4-related disease 0
- Coronary heart disease 262 open
- Anti-NMDA receptor encephalitis 0
- Takayasu arteritis 01 open
- Idiopathic pulmonary fibrosis 19
- Lymphangioleiomyomatosis 0
- Spinal muscular atrophy 1
- Fabry disease 1
- Pompe disease 0
- Duchenne muscular dystrophy 0
- IgA nephropathy 9
- Primary biliary cholangitis 1
- Primary sclerosing cholangitis 0
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 8
- Oesophageal squamous cell carcinoma 27
- Hepatocellular carcinoma 1846 open
- Stomach cancer 1406 open
- Lung cancer 176
- Pancreatic cancer 712 open
- Breast cancer 914 open
- Glioma 561 open
- Hepatoblastoma 3
- Retinoblastoma 2
- Osteosarcoma 12
- Gastrointestinal stromal tumour 7
- Neuroblastoma 1
- Ewing sarcoma 1
- Multiple myeloma 52 open
- B-cell acute lymphoblastic leukaemia 06 open
- Aplastic anaemia 11 open
- Haemophagocytic lymphohistiocytosis 21 open
- Lymphoma 3730 open
- Beta thalassaemia 0
- Haemophilia A 1
- Atypical haemolytic uraemic syndrome 1
- Neuromyelitis optica spectrum disorder 122 open
- IgG4-related disease 52 open
- Myasthenia gravis 4
- Moyamoya disease 461 open
- Coronary heart disease 765 open
- Congenital heart disease 9
- Scoliosis 11
- Anti-NMDA receptor encephalitis 0
- Takayasu arteritis 0
- Hepatic echinococcosis 2
- Idiopathic pulmonary fibrosis 3
- Lymphangioleiomyomatosis 1
- Amyotrophic lateral sclerosis 20
- Spinal muscular atrophy 2
- Fabry disease 3
- Pompe disease 1
- Duchenne muscular dystrophy 6
- Behçet disease 0
- Alport syndrome 1
- IgA nephropathy 171 open
- Gaucher disease 1
- Osteogenesis imperfecta 0
- Primary biliary cholangitis 2
- Familial adenomatous polyposis 0
- Leber hereditary optic neuropathy 1
- Nasopharyngeal carcinoma 331 open
- Oesophageal squamous cell carcinoma 18410 open
- Hepatocellular carcinoma 1033 open
- Stomach cancer 1312 open
- Lung cancer 58725 open
- Pancreatic cancer 452 open
- Breast cancer 33335 open
- Glioma 101 open
- Osteosarcoma 8
- Gastrointestinal stromal tumour 1
- Neuroblastoma 2
- Ewing sarcoma 1
- Aplastic anaemia 3
- Lymphoma 832 open
- Beta thalassaemia 1
- Fanconi anaemia 1
- Idiopathic pulmonary fibrosis 1
- Nasopharyngeal carcinoma 3
- Oesophageal squamous cell carcinoma 41 open
- Hepatocellular carcinoma 6510 open
- Stomach cancer 54
- Lung cancer 21313 open
- Pancreatic cancer 2279 open
- Breast cancer 10610 open
- Glioma 521 open
- Retinoblastoma 0
- Osteosarcoma 4
- Gastrointestinal stromal tumour 6
- Neuroblastoma 71 open
- Ewing sarcoma 1
- Multiple myeloma 272 open
- B-cell acute lymphoblastic leukaemia 1
- Aplastic anaemia 161 open
- Haemophagocytic lymphohistiocytosis 7
- Lymphoma 7410 open
- Beta thalassaemia 1
- Haemophilia A 17
- Atypical haemolytic uraemic syndrome 1
- Thrombotic thrombocytopenic purpura 1
- Neuromyelitis optica spectrum disorder 8
- IgG4-related disease 477 open
- Myasthenia gravis 6
- Moyamoya disease 9
- Coronary heart disease 294 open
- Congenital heart disease 16
- Scoliosis 892 open
- Anti-NMDA receptor encephalitis 3
- Takayasu arteritis 27
- Hepatic echinococcosis 0
- Idiopathic pulmonary fibrosis 18
- Lymphangioleiomyomatosis 14
- Amyotrophic lateral sclerosis 44
- Spinal muscular atrophy 31 open
- Fabry disease 2
- Pompe disease 1
- Duchenne muscular dystrophy 2
- Behçet disease 492 open
- IgA nephropathy 5
- Gaucher disease 1
- Osteogenesis imperfecta 14
- Primary biliary cholangitis 221 open
- Primary sclerosing cholangitis 3
- Congenital diaphragmatic hernia 2
- Hirschsprung disease 1
- Inherited epidermolysis bullosa 1
- Hereditary angioedema 10
- Majeed syndrome 0
- Nasopharyngeal carcinoma 2
- Oesophageal squamous cell carcinoma 826 open
- Hepatocellular carcinoma 425 open
- Stomach cancer 2239 open
- Lung cancer 16122 open
- Pancreatic cancer 342 open
- Breast cancer 11614 open
- Osteosarcoma 4
- Gastrointestinal stromal tumour 121 open
- Neuroblastoma 1
- Ewing sarcoma 2
- Multiple myeloma 3
- Lymphoma 834 open
- Anti-NMDA receptor encephalitis 0
- Hepatocellular carcinoma 202 open
- Stomach cancer 271 open
- Lung cancer 535 open
- Pancreatic cancer 283 open
- Breast cancer 444 open
- Hepatoblastoma 0
- Osteosarcoma 41 open
- Gastrointestinal stromal tumour 2
- Neuroblastoma 6
- Ewing sarcoma 1
- Multiple myeloma 175 open
- Haemophagocytic lymphohistiocytosis 1
- Lymphoma 366 open
- Haemophilia A 1
- Atypical haemolytic uraemic syndrome 2
- Neuromyelitis optica spectrum disorder 1
- IgG4-related disease 5
- Myasthenia gravis 3
- Coronary heart disease 232 open
- Congenital heart disease 5
- Scoliosis 71 open
- Anti-NMDA receptor encephalitis 1
- Takayasu arteritis 1
- Hepatic echinococcosis 1
- Idiopathic pulmonary fibrosis 4
- Amyotrophic lateral sclerosis 2
- Spinal muscular atrophy 1
- Fabry disease 8
- Pompe disease 1
- Duchenne muscular dystrophy 11
- Behçet disease 2
- Alport syndrome 8
- IgA nephropathy 651 open
- Niemann–Pick disease type C 0
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 1
- Hirschsprung disease 1
- Inherited epidermolysis bullosa 5
- Familial adenomatous polyposis 1
- Oesophageal squamous cell carcinoma 2
- Hepatocellular carcinoma 241 open
- Stomach cancer 213 open
- Lung cancer 10214 open
- Pancreatic cancer 31 open
- Breast cancer 4422 open
- Retinoblastoma 0
- Chordoma 6
- Osteosarcoma 442 open
- Gastrointestinal stromal tumour 102 open
- Ewing sarcoma 82 open
- Multiple myeloma 195 open
- B-cell acute lymphoblastic leukaemia 194 open
- Aplastic anaemia 293 open
- Haemophagocytic lymphohistiocytosis 71 open
- Lymphoma 146 open
- Haemophilia A 01 open
- Thrombotic thrombocytopenic purpura 42 open
- Fanconi anaemia 2
- Neuromyelitis optica spectrum disorder 01 open
- IgG4-related disease 121 open
- Myasthenia gravis 3
- Coronary heart disease 13
- Congenital heart disease 5
- Scoliosis 7
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 3
- Behçet disease 51 open
- IgA nephropathy 0
- Gaucher disease 0
- Osteogenesis imperfecta 2
- Primary biliary cholangitis 7
- Primary sclerosing cholangitis 0
- Congenital diaphragmatic hernia 0
- Familial adenomatous polyposis 0
- Hepatocellular carcinoma 121 open
- Stomach cancer 262 open
- Lung cancer 514 open
- Pancreatic cancer 162 open
- Breast cancer 282 open
- Glioma 232 open
- Chordoma 6
- Osteosarcoma 7
- Gastrointestinal stromal tumour 2
- Neuroblastoma 0
- Ewing sarcoma 0
- Multiple myeloma 7
- B-cell acute lymphoblastic leukaemia 0
- Lymphoma 313 open
- Beta thalassaemia 0
- Haemophilia A 1
- Thrombotic thrombocytopenic purpura 0
- Neuromyelitis optica spectrum disorder 2
- IgG4-related disease 2
- Moyamoya disease 2
- Coronary heart disease 172 open
- Congenital heart disease 5
- Scoliosis 41
- Takayasu arteritis 1
- Hepatic echinococcosis 0
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 522 open
- Spinal muscular atrophy 01 open
- Fabry disease 1
- Duchenne muscular dystrophy 1
- Behçet disease 0
- IgA nephropathy 1
- Primary biliary cholangitis 0
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 2
- Hepatocellular carcinoma 15
- Stomach cancer 5
- Lung cancer 262 open
- Pancreatic cancer 6
- Breast cancer 12
- Glioma 25
- Retinoblastoma 0
- Chordoma 7
- Osteosarcoma 1
- Neuroblastoma 3
- B-cell acute lymphoblastic leukaemia 0
- Lymphoma 7
- Beta thalassaemia 1
- Thrombotic thrombocytopenic purpura 1
- Neuromyelitis optica spectrum disorder 52 open
- IgG4-related disease 2
- Myasthenia gravis 161 open
- Moyamoya disease 7
- Coronary heart disease 151 open
- Congenital heart disease 5
- Scoliosis 122 open
- Anti-NMDA receptor encephalitis 9
- Takayasu arteritis 6
- Amyotrophic lateral sclerosis 7
- Duchenne muscular dystrophy 1
- Behçet disease 0
- IgA nephropathy 2
- Niemann–Pick disease type C 1
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lymphoma.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Beijing on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.